Results 71 to 80 of about 6,610 (196)
The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]
Саратовский научно-медицинский журнал, 2016 Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М. +5 more
doaj
BMC Research Notes, 2012 Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V +10 more
doaj +1 more source
BMC Pediatrics, 2009 Background Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of
Mucchino Eleonora +4 more
doaj +1 more source
Jornal de Pediatria (Versão em Português), 2017 Objective: This study aims to describe real world palivizumab use and effectiveness in high‐risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo +5 more
doaj +1 more source
The HMPV F mutant bound motavizumab with higher affinity than palivizumab.
, 2016 Binding of the DS-7 Fab to wild-type (a) and motavizumab Fab RPM-1 (b) proteins using a BiOptix 404pi instrument. The wild-type HMPV F protein bound DS-7 with similar affinity as measured with the Biorad Proteon (Table 1).
Xiaolin Wen (2806171) +6 more
core +1 more source
Respiratory syncytial virus infection and palivizumab: are families receiving accurate information
, 2012 The aim of this study was to assess the accuracy of information provided by medical practitioners to families regarding the efficacy and limitations of prophylaxis with palivizumab for respiratory syncytial virus (RSV) infection in infants.
Weiner, Joel H.
core +1 more source
Effect of Palivizumab Prophylaxis in High Risk Newborns of 2016-2018. [PDF]
, 2020 Aim: To analyze the impact of palivizumab prophylaxis in minimizing the occurrence of respiratory diseases. Objectives: 1. To compare the morbidity between fully immunized newborns and partially immunized newborns. 2.
Joneliūnaitė, Vaiva
core
Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children [PDF]
, 2017 Respiratory syncytial virus (RSV) infection can cause lower respiratory tract disease and mortality in pediatric hematopoietic stem cell transplant (HSCT) recipients. We report two children who underwent HSCT and developed RSV infection simultaneously at
Torres Torretti, Juan Pablo +9 more
core +1 more source
Oman Medical JournalRespiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Adel S. Alharbi +7 more
doaj +1 more source
Structural elucidation of the interactions between F glycoprotein and palivizumab.
, 2019 (a) Predicted structure of the RSV-A postfusion F glycoprotein (PDB: 3RRT) bound to palivizumab Fab fragment (PBD: 2HWZ). Pink dots, antigenic site II (amino acid residues 258–275); upper panel, side view; lower panel, top view.
Rabih Andary (6387881) +11 more
core +1 more source